PEGPH20
PCRT 16-001
Phase 2 small_molecule active
Quick answer
PEGPH20 for Pancreatic Ductal Adenocarcinoma is a Phase 2 program (small_molecule) at HALOZYME THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- HALOZYME THERAPEUTICS, INC.
- Indication
- Pancreatic Ductal Adenocarcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active